Department of Psychology, Indiana University, Indianapolis, USA.
Alcohol Clin Exp Res. 2012 May;36(5):881-6. doi: 10.1111/j.1530-0277.2011.01653.x. Epub 2011 Oct 7.
Previous studies show that prazosin, an α(1) -adrenergic receptor antagonist, decreases alcohol drinking in animal models of alcohol use and dependence [Rasmussen et al. (2009) Alcohol Clin Exp Res 3:264-272; Walker et al. (2008) Alcohol 42:91-97] and in alcohol-dependent men [Simpson et al. (2009) Alcohol Clin Exp Res 33:255-263]. This study extended these findings by using a paradigm that allows for separate assessment of prazosin on motivation to seek versus consume alcohol or sucrose in selectively bred rats.
Alcohol-preferring (P) rats were trained to complete an operant response that resulted in access to either 2% sucrose or 10% alcohol. A 4-week Seeking Test Phase examined responding in single, weekly extinction sessions when no reinforcer could be obtained. A 4-week Drinking Test Phase consisted of rats lever-pressing to "pay" a specified amount up front to gain access to unlimited alcohol (or sucrose) for a 20-minute period. On Seeking and Drinking test days, prazosin (0.0, 0.5, 1.0, and 1.5 mg/kg) was administered intraperitoneally 30 minutes prior to behavioral sessions.
Rats were self-administering an average of 0.9 (±0.09) g/kg alcohol on vehicle test day and had pharmacologically relevant blood ethanol concentrations. Prazosin significantly decreased alcohol seeking at all doses tested. The highest dose of prazosin also increased the latency to first response for alcohol and decreased alcohol intake. While sucrose-seeking and intake were similarly affected by prazosin, the high dose of prazosin did not increase response latency.
These findings are consistent with and extend previous research and suggest that prazosin decreases motivation to initiate and engage in alcohol consumption. The specificity of prazosin in attenuating the initiation of alcohol- but not sucrose-seeking suggests that this effect is not because of prazosin-induced motor-impairment or malaise. Together with previous findings, these data suggest that prazosin may be an effective pharmacotherapy, with specific application in people that drink excessively or have a genetic predisposition to alcohol abuse.
先前的研究表明,α(1)肾上腺素能受体拮抗剂哌唑嗪可减少动物模型中酒精使用和依赖[Rasmussen 等人(2009)《酒精临床与实验研究》3:264-272;Walker 等人(2008)《酒精》42:91-97]和酒精依赖男性[ Simpson 等人(2009)《酒精临床与实验研究》33:255-263]的饮酒。本研究通过使用一种范式来扩展这些发现,该范式允许单独评估哌唑嗪对选择性繁殖大鼠寻求与消耗酒精或蔗糖的动机的影响。
酒精偏好(P)大鼠接受训练,以完成一项操作性反应,从而获得 2%蔗糖或 10%酒精。为期 4 周的寻求测试阶段检查了在每周一次的单一消退阶段的反应,此时无法获得强化物。为期 4 周的饮酒测试阶段由大鼠操纵杆按下以“支付”指定金额,以提前获得无限量的酒精(或蔗糖)20 分钟。在寻求和饮酒测试日,哌唑嗪(0.0、0.5、1.0 和 1.5 mg/kg)在行为学测试前 30 分钟腹膜内给药。
大鼠在载体测试日平均自我给药 0.9(±0.09)g/kg 酒精,并且具有药理学相关的血乙醇浓度。哌唑嗪在所有测试剂量下均显著减少酒精的寻求。最高剂量的哌唑嗪还增加了对酒精的首次反应潜伏期,并减少了酒精摄入量。虽然蔗糖的寻求和摄入量也受到哌唑嗪的影响,但高剂量的哌唑嗪并未增加反应潜伏期。
这些发现与先前的研究一致,并表明哌唑嗪可降低开始和参与饮酒的动机。哌唑嗪在减弱酒精而非蔗糖寻求的启动方面的特异性表明,这种作用不是由于哌唑嗪引起的运动障碍或不适。与先前的发现一起,这些数据表明哌唑嗪可能是一种有效的药物治疗方法,特别适用于过度饮酒或有酒精滥用遗传倾向的人。